Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Venetoclax with decitabine for high-risk AML and MDS

Abhishek Maiti, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, outlines a Phase II study (NCT03404193) of venetoclax in combination with 10-day decitabine in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia (AML) and relapsed high-risk myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).